fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 1

Conditions: Social Anxiety Disorder

Treatments: Drug: GW679769

Study type: Interventional

Funder types: Industry

Identifiers

NCT00332046

NKF10015

Details and patient eligibility

About

Evidence suggests the use of neuroimaging to detect therapeutic effects of anxiolytic treatment when appropriate cognitive-emotional tasks are use to activate the emotional brain neurocircuitry believed to be involved in the core symptoms of the disease.

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary diagnosis of Social Anxiety Disorder.
• Willing to restrict alcohol to a limited intake.

Exclusion criteria

• History of schizophrenia, schizoaffective disorder or a bipolar disorder.
• Left-handed.
• Suffer from claustrophobia.
• Any reason why subject could not go into the fMRI, for example have metal implants.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind